{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T09:13:35Z","timestamp":1790327615239,"version":"4.1.0"},"reference-count":126,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RO1 DK105448"],"award-info":[{"award-number":["RO1 DK105448"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CTSA","award":["UL1RR024982"],"award-info":[{"award-number":["UL1RR024982"]}]},{"name":"CTSA","award":["UL1TR001105"],"award-info":[{"award-number":["UL1TR001105"]}]},{"name":"Southwestern Medical Foundation"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.pathol.2018.11.004","type":"journal-article","created":{"date-parts":[[2018,12,27]],"date-time":"2018-12-27T08:46:48Z","timestamp":1545900408000},"page":"202-212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":99,"title":["Lipodystrophies, dyslipidaemias and atherosclerotic cardiovascular disease"],"prefix":"10.1016","volume":"51","author":[{"given":"Iram","family":"Hussain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nivedita","family":"Patni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7209-6986","authenticated-orcid":false,"given":"Abhimanyu","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2018.11.004_bib1","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.ecl.2016.06.012","article-title":"Lipodystrophy syndromes","volume":"45","author":"Hussain","year":"2016","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.pathol.2018.11.004_bib2","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2147\/DMSO.S130810","article-title":"Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges","volume":"10","author":"Chiquette","year":"2017","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.pathol.2018.11.004_bib3","series-title":"HIV-Associated Lipodystrophy","author":"Guzman","year":"2018"},{"key":"10.1016\/j.pathol.2018.11.004_bib4","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.trsl.2016.12.007","article-title":"HIV and its relationship to insulin resistance and lipid abnormalities","volume":"183","author":"Non","year":"2017","journal-title":"Transl Res"},{"key":"10.1016\/j.pathol.2018.11.004_bib5","first-page":"559","article-title":"HIV-associated lipodystrophy: a review from a Brazilian perspective","volume":"10","author":"Alves","year":"2014","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.pathol.2018.11.004_bib6","first-page":"253","article-title":"Lipodystrophy: beyond generalization?","volume":"55","author":"Freitas","year":"2013","journal-title":"Panminerva Med"},{"key":"10.1016\/j.pathol.2018.11.004_bib7","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nrendo.2015.123","article-title":"Congenital generalized lipodystrophies\u2013new insights into metabolic dysfunction","volume":"11","author":"Patni","year":"2015","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.pathol.2018.11.004_bib8","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1056\/NEJMra025261","article-title":"Acquired and inherited lipodystrophies","volume":"350","author":"Garg","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2018.11.004_bib9","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1210\/jc.2007-1328","article-title":"Association of a homozygous nonsense caveolin-1 mutation with Berardinelli-Seip congenital lipodystrophy","volume":"93","author":"Kim","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.pathol.2018.11.004_bib10","doi-asserted-by":"crossref","first-page":"e1000874","DOI":"10.1371\/journal.pgen.1000874","article-title":"Fatal cardiac arrhythmia and long-QT syndrome in a new form of congenital generalized lipodystrophy with muscle rippling (CGL4) due to PTRF-CAVIN mutations","volume":"6","author":"Rajab","year":"2010","journal-title":"PLoS Genet"},{"key":"10.1016\/j.pathol.2018.11.004_bib11","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1172\/JCI38660","article-title":"Human PTRF mutations cause secondary deficiency of caveolins resulting in muscular dystrophy with generalized lipodystrophy","volume":"119","author":"Hayashi","year":"2009","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.pathol.2018.11.004_bib12","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1002\/ajmg.a.32457","article-title":"Novel subtype of congenital generalized lipodystrophy associated with muscular weakness and cervical spine instability","volume":"146A","author":"Simha","year":"2008","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.pathol.2018.11.004_bib13","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1002\/ajmg.a.33578","article-title":"Congenital generalized lipodystrophy, type 4 (CGL4) associated with myopathy due to novel PTRF mutations","volume":"152A","author":"Shastry","year":"2010","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.pathol.2018.11.004_bib14","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ymgme.2010.06.016","article-title":"A\u00a0Japanese child with asymptomatic elevation of serum creatine kinase shows PTRF-CAVIN mutation matching with congenital generalized lipodystrophy type 4","volume":"101","author":"Dwianingsih","year":"2010","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.pathol.2018.11.004_bib15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1471-2350-14-89","article-title":"Novel PTRF mutation in a child with mild myopathy and very mild congenital lipodystrophy","volume":"14","author":"Ardissone","year":"2013","journal-title":"BMC Med Genet"},{"key":"10.1016\/j.pathol.2018.11.004_bib16","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ejmg.2016.05.001","article-title":"Spectrum of clinical manifestations in two young Turkish patients with congenital generalized lipodystrophy type 4","volume":"59","author":"Akinci","year":"2016","journal-title":"Eur J Med Genet"},{"key":"10.1016\/j.pathol.2018.11.004_bib17","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ejmg.2015.02.002","article-title":"Novel nonsense mutation in the PTRF gene underlies congenital generalized lipodystrophy in a consanguineous Saudi family","volume":"58","author":"Jelani","year":"2015","journal-title":"Eur J Med Genet"},{"key":"10.1016\/j.pathol.2018.11.004_bib18","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.nmd.2013.02.005","article-title":"Congenital generalized lipodystrophy type 4 with muscular dystrophy: clinical and pathological manifestations in early childhood","volume":"23","author":"Murakami","year":"2013","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.pathol.2018.11.004_bib19","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1651-2227.1996.tb14262.x","article-title":"Generalized lipodystrophy, congenital and acquired (lipoatrophy)","volume":"413","author":"Seip","year":"1996","journal-title":"Acta Paediatr Suppl"},{"key":"10.1016\/j.pathol.2018.11.004_bib20","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1651-2227.1996.tb14265.x","article-title":"Radiological features in generalized lipodystrophy","volume":"413","author":"Westvik","year":"1996","journal-title":"Acta Paediatr Suppl"},{"key":"10.1016\/j.pathol.2018.11.004_bib21","first-page":"358","article-title":"Peculiar distribution of adipose tissue in patients with congenital generalized lipodystrophy","volume":"75","author":"Garg","year":"1992","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.pathol.2018.11.004_bib22","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1136\/jmg.39.10.722","article-title":"Genotype-phenotype relationships in Berardinelli-Seip congenital lipodystrophy","volume":"39","author":"Van Maldergem","year":"2002","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.pathol.2018.11.004_bib23","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1210\/jc.2003-030855","article-title":"Phenotypic and genetic heterogeneity in congenital generalized lipodystrophy","volume":"88","author":"Agarwal","year":"2003","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.pathol.2018.11.004_bib24","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S1043-2760(03)00078-X","article-title":"Congenital generalized lipodystrophy: significance of triglyceride biosynthetic pathways","volume":"14","author":"Agarwal","year":"2003","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.pathol.2018.11.004_bib25","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1056\/NEJMoa012437","article-title":"Leptin-replacement therapy for lipodystrophy","volume":"346","author":"Oral","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2018.11.004_bib26","first-page":"109","article-title":"Cardiometabolic abnormalities in patients with Berardinelli-Seip syndrome. (Portuguese.)","volume":"94","author":"Rego","year":"2010","journal-title":"Arq Bras Cardiol"},{"key":"10.1016\/j.pathol.2018.11.004_bib27","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1210\/jc.2016-2271","article-title":"Clinical features and management of non-HIV-related lipodystrophy in children: a systematic review","volume":"102","author":"Gupta","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.pathol.2018.11.004_bib28","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1210\/jcem.84.9.6103","article-title":"A\u00a0gene for congenital generalized lipodystrophy maps to human chromosome 9q34","volume":"84","author":"Garg","year":"1999","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.pathol.2018.11.004_bib29","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/ng880","article-title":"AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34","volume":"31","author":"Agarwal","year":"2002","journal-title":"Nat Genet"},{"key":"10.1016\/j.pathol.2018.11.004_bib30","doi-asserted-by":"crossref","first-page":"5433","DOI":"10.1210\/jc.2003-030835","article-title":"Phenotypic heterogeneity in body fat distribution in patients with congenital generalized lipodystrophy due to mutations in the AGPAT2 or Seipin genes","volume":"88","author":"Simha","year":"2003","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.pathol.2018.11.004_bib31","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/MD.0b013e3181e9442f","article-title":"Cardiomyopathy in congenital and acquired generalized lipodystrophy: a clinical assessment","volume":"89","author":"Lupsa","year":"2010","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.pathol.2018.11.004_bib32","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0022-3476(86)80389-4","article-title":"Hypertrophic cardiomyopathy in total lipodystrophy","volume":"109","author":"Rheuban","year":"1986","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.pathol.2018.11.004_bib33","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1210\/jc.2016-1005","article-title":"Natural history of congenital generalized lipodystrophy: a nationwide study from Turkey","volume":"101","author":"Akinci","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.pathol.2018.11.004_bib34","first-page":"3077","article-title":"Postmortem findings in congenital generalized lipodystrophy","volume":"80","author":"Chandalia","year":"1995","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.pathol.2018.11.004_bib35","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/ng585","article-title":"Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13","volume":"28","author":"Magre","year":"2001","journal-title":"Nat Genet"},{"key":"10.1016\/j.pathol.2018.11.004_bib36","doi-asserted-by":"crossref","first-page":"20890","DOI":"10.1073\/pnas.0704154104","article-title":"The lipodystrophy protein seipin is found at endoplasmic reticulum lipid droplet junctions and is important for droplet morphology","volume":"104","author":"Szymanski","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pathol.2018.11.004_bib37","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1083\/jcb.200711136","article-title":"Fld1p, a functional homologue of human seipin, regulates the size of lipid droplets in yeast","volume":"180","author":"Fei","year":"2008","journal-title":"J\u00a0Cell Biol"},{"key":"10.1016\/j.pathol.2018.11.004_bib38","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1042\/BJ20121870","article-title":"Seipin differentially regulates lipogenesis and adipogenesis through a conserved core sequence and an evolutionarily acquired C-terminus","volume":"452","author":"Yang","year":"2013","journal-title":"Biochem J"},{"key":"10.1016\/j.pathol.2018.11.004_bib39","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1746-1596-8-78","article-title":"Deletion mutation in BSCL2 gene underlies congenital generalized lipodystrophy in a Pakistani family","volume":"8","author":"Rahman","year":"2013","journal-title":"Diag Pathol"},{"key":"10.1016\/j.pathol.2018.11.004_bib40","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1034\/j.1399-0004.2002.610407.x","article-title":"Cardiomyopathy in congenital complete lipodystrophy","volume":"61","author":"Bhayana","year":"2002","journal-title":"Clin Genet"},{"key":"10.1016\/j.pathol.2018.11.004_bib41","doi-asserted-by":"crossref","first-page":"e0199052","DOI":"10.1371\/journal.pone.0199052","article-title":"Causes of death in patients with Berardinelli-Seip congenital generalized lipodystrophy","volume":"13","author":"Lima","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.pathol.2018.11.004_bib42","article-title":"Post mortem findings in a young male with congenital generalized lipodystrophy, type 4 due to CAVIN1 mutations","author":"Patni","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.pathol.2018.11.004_bib43","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/hmg\/9.1.109","article-title":"Nuclear lamin A\/C R482Q mutation in Canadian kindreds with Dunnigan-type familial partial lipodystrophy","volume":"9","author":"Cao","year":"2000","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.pathol.2018.11.004_bib44","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/ng0398-292","article-title":"Localization of the gene for familial partial lipodystrophy (Dunnigan variety) to chromosome 1q21-22","volume":"18","author":"Peters","year":"1998","journal-title":"Nat Genet"},{"key":"10.1016\/j.pathol.2018.11.004_bib45","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/MOL.0b013e32832d4a33","article-title":"Inherited lipodystrophies and hypertriglyceridemia","volume":"20","author":"Simha","year":"2009","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.pathol.2018.11.004_bib46","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/72807","article-title":"LMNA, encoding lamin A\/C, is mutated in partial lipodystrophy","volume":"24","author":"Shackleton","year":"2000","journal-title":"Nat Genet"},{"key":"10.1016\/j.pathol.2018.11.004_bib47","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1086\/302836","article-title":"Mutational and haplotype analyses of families with familial partial lipodystrophy (Dunnigan variety) reveal recurrent missense mutations in the globular C-terminal domain of lamin A\/C","volume":"66","author":"Speckman","year":"2000","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.pathol.2018.11.004_bib48","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.ahj.2014.12.021","article-title":"Metabolic and cardiac phenotype characterization in 37 atypical Dunnigan patients with nonfarnesylated mutated prelamin A","volume":"169","author":"Andre","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.pathol.2018.11.004_bib49","first-page":"1776","article-title":"Gender differences in the prevalence of metabolic complications in familial partial lipodystrophy (Dunnigan variety)","volume":"85","author":"Garg","year":"2000","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.pathol.2018.11.004_bib50","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1161\/01.ATV.0000047460.27435.B8","article-title":"Elevated serum C-reactive protein and free fatty acids among nondiabetic carriers of missense mutations in the gene encoding lamin A\/C (LMNA) with partial lipodystrophy","volume":"23","author":"Hegele","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pathol.2018.11.004_bib51","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.metabol.2017.04.010","article-title":"Clinical presentations, metabolic abnormalities and end-organ complications in patients with familial partial lipodystrophy","volume":"72","author":"Akinci","year":"2017","journal-title":"Metabolism"},{"key":"10.1016\/j.pathol.2018.11.004_bib52","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1161\/01.CIR.103.18.2225","article-title":"Premature atherosclerosis associated with monogenic insulin resistance","volume":"103","author":"Hegele","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.pathol.2018.11.004_bib53","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s13353-016-0365-2","article-title":"Limb-girdle muscular dystrophy with severe heart failure overlapping with lipodystrophy in a patient with LMNA mutation p.Ser334del","volume":"58","author":"Madej-Pilarczyk","year":"2017","journal-title":"J\u00a0Appl Genet"},{"key":"10.1016\/j.pathol.2018.11.004_bib54","first-page":"3431","article-title":"Heterogeneity of nuclear lamin A mutations in Dunnigan-type familial partial lipodystrophy","volume":"85","author":"Hegele","year":"2000","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.pathol.2018.11.004_bib55","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.2337\/diacare.26.5.1350","article-title":"Risk factors for diabetes in familial partial lipodystrophy, Dunnigan variety","volume":"26","author":"Haque","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pathol.2018.11.004_bib56","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1046\/j.1464-5491.2002.00796.x","article-title":"Post-mortem findings in familial partial lipodystrophy, Dunnigan variety","volume":"19","author":"Haque","year":"2002","journal-title":"Diabet Med"},{"key":"10.1016\/j.pathol.2018.11.004_bib57","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1212\/WNL.59.4.620","article-title":"Lamin A\/C mutations with lipodystrophy, cardiac abnormalities, and muscular dystrophy","volume":"59","author":"van der Kooi","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.pathol.2018.11.004_bib58","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1046\/j.1464-5491.2003.01034.x","article-title":"Response to treatment with rosiglitazone in familial partial lipodystrophy due to a mutation in the LMNA gene","volume":"20","author":"Owen","year":"2003","journal-title":"Diabet Med"},{"key":"10.1016\/j.pathol.2018.11.004_bib59","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00125-004-1360-4","article-title":"Familial partial lipodystrophy associated with compound heterozygosity for novel mutations in the LMNA gene","volume":"47","author":"Savage","year":"2004","journal-title":"Diabetologia"},{"key":"10.1016\/j.pathol.2018.11.004_bib60","doi-asserted-by":"crossref","first-page":"5337","DOI":"10.1210\/jc.2003-031658","article-title":"Patients with familial partial lipodystrophy of the Dunnigan type due to a LMNA R482W mutation show muscular and cardiac abnormalities","volume":"89","author":"Vantyghem","year":"2004","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.pathol.2018.11.004_bib61","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1399-0004.2009.01350.x","article-title":"Overlapping syndrome with familial partial lipodystrophy, Dunnigan variety and cardiomyopathy due to amino-terminal heterozygous missense lamin A\/C mutations","volume":"78","author":"Subramanyam","year":"2010","journal-title":"Clin Genet"},{"key":"10.1016\/j.pathol.2018.11.004_bib62","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1210\/jc.2007-2521","article-title":"Fertility and obstetrical complications in women with LMNA-related familial partial lipodystrophy","volume":"93","author":"Vantyghem","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.pathol.2018.11.004_bib63","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2265.2007.03146.x","article-title":"A\u00a0novel phenotypic expression associated with a new mutation in LMNA gene, characterized by partial lipodystrophy, insulin resistance, aortic stenosis and hypertrophic cardiomyopathy","volume":"69","author":"Araujo-Vilar","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.pathol.2018.11.004_bib64","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jcjd.2015.12.007","article-title":"A\u00a0case of familial partial lipodystrophy: from clinical phenotype to genetics","volume":"40","author":"Vouillarmet","year":"2016","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.pathol.2018.11.004_bib65","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12887-016-0581-2","article-title":"Fitting the pieces of the puzzle together: a case report of the Dunnigan-type of familial partial lipodystrophy in the adolescent girl","volume":"16","author":"Krawiec","year":"2016","journal-title":"BMC Pediatr"},{"key":"10.1016\/j.pathol.2018.11.004_bib66","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejim.2015.12.012","article-title":"A\u00a0case of familial partial lipodystrophy caused by a novel lamin A\/C (LMNA) mutation in exon 1 (D47N)","volume":"29","author":"Kutbay","year":"2016","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.pathol.2018.11.004_bib67","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1111\/dme.13061","article-title":"Familial partial lipodystrophy linked to a novel peroxisome proliferator activator receptor -gamma (PPARG) mutation, H449L: a comparison of people with this mutation and those with classic codon 482 Lamin A\/C (LMNA) mutations","volume":"33","author":"Demir","year":"2016","journal-title":"Diabet Med"},{"key":"10.1016\/j.pathol.2018.11.004_bib68","doi-asserted-by":"crossref","first-page":"550","DOI":"10.5603\/EP.2015.0067","article-title":"Familial partial lipodystrophy as differential diagnosis of polycystic ovary syndrome","volume":"66","author":"Lewandowski","year":"2015","journal-title":"Endokrynol Pol"},{"key":"10.1016\/j.pathol.2018.11.004_bib69","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13104-015-1065-4","article-title":"Familial partial lipodystrophy, Dunnigan variety \u2013 challenges for patient care during pregnancy: a case report","volume":"8","author":"Belo","year":"2015","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.pathol.2018.11.004_bib70","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.diabet.2013.12.008","article-title":"LMNA gene mutation as a model of cardiometabolic dysfunction: from genetic analysis to treatment response","volume":"40","author":"Chirico","year":"2014","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.pathol.2018.11.004_bib71","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000354716","article-title":"Cosegregation of focal segmental glomerulosclerosis in a family with familial partial lipodystrophy due to a mutation in LMNA","volume":"124","author":"Thong","year":"2013","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.pathol.2018.11.004_bib72","doi-asserted-by":"crossref","first-page":"306","DOI":"10.5603\/EP.2013.0010","article-title":"Dunnigan-type familial partial lipodystrophy associated with the heterozygous R482W mutation in LMNA gene \u2013 case study of three women from one family","volume":"64","author":"Nabrdalik","year":"2013","journal-title":"Endokrynol Pol"},{"key":"10.1016\/j.pathol.2018.11.004_bib73","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.nmd.2013.04.008","article-title":"Multisystem disorder and limb girdle muscular dystrophy caused by LMNA p.R28W mutation","volume":"23","author":"Turk","year":"2013","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.pathol.2018.11.004_bib74","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.atherosclerosis.2013.04.016","article-title":"A\u00a0novel lamin A\/C mutation in a Dutch family with premature atherosclerosis","volume":"229","author":"Weterings","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pathol.2018.11.004_bib75","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1530\/EJE-12-0268","article-title":"Phenotypic diversity in patients with lipodystrophy associated with LMNA mutations","volume":"167","author":"Mory","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.pathol.2018.11.004_bib76","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/j.1365-2265.2011.04208.x","article-title":"Histological and molecular features of lipomatous and nonlipomatous adipose tissue in familial partial lipodystrophy caused by LMNA mutations","volume":"76","author":"Araujo-Vilar","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.pathol.2018.11.004_bib77","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1055\/s-0028-1128138","article-title":"Comparison of phenotypes in male and female individuals of a new family with Dunnigan type of familial partial lipodystrophy due to a lamin A\/C R482W mutation","volume":"41","author":"Laudes","year":"2009","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.pathol.2018.11.004_bib78","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.diabet.2007.04.005","article-title":"Efficacy of pioglitazone in familial partial lipodystrophy of the Dunnigan type: a case report","volume":"33","author":"Moreau","year":"2007","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.pathol.2018.11.004_bib79","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1503\/cmaj.070135","article-title":"Obstructive sleep apnea in 2 women with familial partial lipodystrophy due to a heterozygous LMNA R482Q mutation","volume":"177","author":"Hegele","year":"2007","journal-title":"CMAJ"},{"key":"10.1016\/j.pathol.2018.11.004_bib80","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1210\/jc.2007-0654","article-title":"New metabolic phenotypes in laminopathies: LMNA mutations in patients with severe metabolic syndrome","volume":"92","author":"Decaudain","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.pathol.2018.11.004_bib81","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1365-2265.2007.02870.x","article-title":"Familial partial lipodystrophy due to the LMNA R482W mutation with multinodular goitre, extrapyramidal syndrome and primary hyperaldosteronism","volume":"67","author":"Vantyghem","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.pathol.2018.11.004_bib82","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1399-0004.2007.00740.x","article-title":"Novel LMNA mutations seen in patients with familial partial lipodystrophy subtype 2 (FPLD2; MIM 151660)","volume":"71","author":"Lanktree","year":"2007","journal-title":"Clin Genet"},{"key":"10.1016\/j.pathol.2018.11.004_bib83","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1111\/j.1464-5491.2005.01757.x","article-title":"Long-term treatment experience in a subject with Dunnigan-type familial partial lipodystrophy: efficacy of rosiglitazone","volume":"22","author":"Ludtke","year":"2005","journal-title":"Diabet Med"},{"key":"10.1016\/j.pathol.2018.11.004_bib84","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1111\/j.1572-0241.2005.00234.x","article-title":"Hepatic steatosis in Dunnigan-type familial partial lipodystrophy","volume":"100","author":"Ludtke","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.pathol.2018.11.004_bib85","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2337\/diabetes.54.6.1873","article-title":"Type A insulin resistance syndrome revealing a novel lamin A mutation","volume":"54","author":"Young","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.pathol.2018.11.004_bib86","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0028-3843(14)60044-X","article-title":"Familial partial lipodystrophy associated with the heterozygous LMNA mutation 1445G>A (Arg482Gln) in a Polish family","volume":"44","author":"Drac","year":"2010","journal-title":"Neurol Neurochir Pol"},{"key":"10.1016\/j.pathol.2018.11.004_bib87","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s12020-009-9265-0","article-title":"LMNA gene mutation search in Polish patients: new features of the heterozygous Arg482Gln mutation phenotype","volume":"36","author":"Klupa","year":"2009","journal-title":"Endocrine"},{"key":"10.1016\/j.pathol.2018.11.004_bib88","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/AOG.0b013e31819feaa9","article-title":"Lipodystrophy: an unusual diagnosis in a case of oligomenorrhea and hirsutism","volume":"114","author":"Keller","year":"2009","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.pathol.2018.11.004_bib89","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s11325-009-0261-7","article-title":"Obstructive sleep apnea in familial partial lipodystrophy type 2 with atypical skin findings and vascular disease","volume":"13","author":"Patel","year":"2009","journal-title":"Sleep Breath"},{"key":"10.1016\/j.pathol.2018.11.004_bib90","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s12020-008-9127-1","article-title":"A\u00a0case of Dunnigan-type familial partial lipodystrophy (FPLD) due to lamin A\/C (LMNA) mutations complicated by end-stage renal disease","volume":"35","author":"Imachi","year":"2009","journal-title":"Endocrine"},{"key":"10.1016\/j.pathol.2018.11.004_bib91","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1210\/jcem.86.5.7500","article-title":"Dyslipemia in familial partial lipodystrophy caused by an R482W mutation in the LMNA gene","volume":"86","author":"Schmidt","year":"2001","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.pathol.2018.11.004_bib92","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1210\/jc.2005-2746","article-title":"A\u00a0LMNA splicing mutation in two sisters with severe Dunnigan-type familial partial lipodystrophy type 2","volume":"91","author":"Morel","year":"2006","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.pathol.2018.11.004_bib93","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1002\/ajmg.a.32331","article-title":"Extreme phenotypic diversity and nonpenetrance in families with the LMNA gene mutation R644C","volume":"146A","author":"Rankin","year":"2008","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.pathol.2018.11.004_bib94","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1016\/j.ajpath.2011.07.049","article-title":"LMNA mutations induce a non-inflammatory fibrosis and a brown fat-like dystrophy of enlarged cervical adipose tissue","volume":"179","author":"Bereziat","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1016\/j.pathol.2018.11.004_bib95","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1530\/EJE-08-0272","article-title":"Monogenic polycystic ovary syndrome due to a mutation in the lamin A\/C gene is sensitive to thiazolidinediones but not to metformin","volume":"159","author":"Gambineri","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.pathol.2018.11.004_bib96","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.nmd.2012.11.011","article-title":"Homozygous lamin A\/C familial lipodystrophy R482Q mutation in autosomal recessive Emery Dreifuss muscular dystrophy","volume":"23","author":"Wiltshire","year":"2013","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.pathol.2018.11.004_bib97","doi-asserted-by":"crossref","first-page":"E856","DOI":"10.1210\/jc.2010-2234","article-title":"A\u00a0homozygous mutation of prelamin-A preventing its farnesylation and maturation leads to a severe lipodystrophic phenotype: new insights into the pathogenicity of nonfarnesylated prelamin-A","volume":"96","author":"Le Dour","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.pathol.2018.11.004_bib98","first-page":"59","article-title":"Phenotypic heterogeneity in patients with familial partial lipodystrophy (Dunnigan variety) related to the site of missense mutations in lamin A\/C gene","volume":"86","author":"Garg","year":"2001","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.pathol.2018.11.004_bib99","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/72807","article-title":"LMNA, encoding lamin A\/C, is mutated in partial lipodystrophy","volume":"24","author":"Shackleton","year":"2000","journal-title":"Nat Genet"},{"key":"10.1016\/j.pathol.2018.11.004_bib100","first-page":"7","article-title":"Overlapping syndromes in laminopathies: a meta-analysis of the reported literature","volume":"32","author":"Carboni","year":"2013","journal-title":"Acta Myol"},{"key":"10.1016\/j.pathol.2018.11.004_bib101","doi-asserted-by":"crossref","first-page":"136","DOI":"10.4103\/2230-8210.91209","article-title":"Body fat distribution in women with familial partial lipodystrophy caused by mutation in the lamin A\/C gene","volume":"16","author":"Monteiro","year":"2012","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.pathol.2018.11.004_bib102","doi-asserted-by":"crossref","first-page":"3779","DOI":"10.1093\/hmg\/ddr294","article-title":"High prevalence of laminopathies among patients with metabolic syndrome","volume":"20","author":"Dutour","year":"2011","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.pathol.2018.11.004_bib103","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1212\/01.wnl.0000255939.73424.f8","article-title":"Muscle and nerve pathology in Dunnigan familial partial lipodystrophy","volume":"68","author":"Spuler","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.pathol.2018.11.004_bib104","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1055\/s-2003-38388","article-title":"Phenotypic gender differences in subjects with familial partial lipodystrophy (Dunnigan variety) due to a nuclear lamin A\/C R482W mutation","volume":"35","author":"Araujo-Vilar","year":"2003","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.pathol.2018.11.004_bib105","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1210\/jc.2009-1293","article-title":"LMNA mutations, skeletal muscle lipid metabolism, and insulin resistance","volume":"95","author":"Boschmann","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.pathol.2018.11.004_bib106","first-page":"408","article-title":"A\u00a0novel heterozygous mutation in peroxisome proliferator-activated receptor-g gene in a patient with familial partial lipodystrophy","volume":"87","author":"Agarwal","year":"2002","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.pathol.2018.11.004_bib107","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.cmet.2006.09.003","article-title":"Non-DNA binding, dominant-negative, human PPARgamma mutations cause lipodystrophic insulin resistance","volume":"4","author":"Agostini","year":"2006","journal-title":"Cell Metab"},{"key":"10.1016\/j.pathol.2018.11.004_bib108","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/01.md.0000111061.69212.59","article-title":"Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature","volume":"83","author":"Misra","year":"2004","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.pathol.2018.11.004_bib109","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.3389\/fimmu.2018.02142","article-title":"Autoantibodies against perilipin 1 as a cause of acquired generalized lipodystrophy","volume":"9","author":"Corvillo","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.pathol.2018.11.004_bib110","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/00005792-200303000-00007","article-title":"Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature","volume":"82","author":"Misra","year":"2003","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.pathol.2018.11.004_bib111","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1210\/jcem-52-3-416","article-title":"Heterogeneity of the insulin-receptor interaction in lipoatropic diabetes","volume":"52","author":"Wachslicht-Rodbard","year":"1981","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.pathol.2018.11.004_bib112","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1210\/jc.2008-1703","article-title":"Complement abnormalities in acquired lipodystrophy revisited","volume":"94","author":"Savage","year":"2009","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.pathol.2018.11.004_bib113","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3109\/10428194.2015.1040015","article-title":"Lymphoma in acquired generalized lipodystrophy","volume":"57","author":"Brown","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.pathol.2018.11.004_bib114","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1210\/jc.2016-2466","article-title":"The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline","volume":"101","author":"Brown","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.pathol.2018.11.004_bib115","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s12020-014-0450-4","article-title":"Recombinant human leptin treatment in genetic lipodystrophic syndromes: the long-term Spanish experience","volume":"49","author":"Araujo-Vilar","year":"2014","journal-title":"Endocrine"},{"key":"10.1016\/j.pathol.2018.11.004_bib116","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.1542\/peds.2006-3165","article-title":"Metabolic correction induced by leptin replacement treatment in young children with Berardinelli-Seip congenital lipoatrophy","volume":"120","author":"Beltrand","year":"2007","journal-title":"Pediatrics"},{"key":"10.1016\/j.pathol.2018.11.004_bib117","doi-asserted-by":"crossref","first-page":"922","DOI":"10.4158\/EP11229.OR","article-title":"Clinical effects of long-term metreleptin treatment in patients with lipodystrophy","volume":"17","author":"Chan","year":"2011","journal-title":"Endocr Pract"},{"key":"10.1016\/j.pathol.2018.11.004_bib118","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jhep.2013.02.007","article-title":"The liver diseases of lipodystrophy: the long-term effect of leptin treatment","volume":"59","author":"Safar Zadeh","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.pathol.2018.11.004_bib119","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1210\/jc.2006-1546","article-title":"Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy","volume":"92","author":"Ebihara","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.pathol.2018.11.004_bib120","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1210\/jc.2014-4491","article-title":"Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin","volume":"100","author":"Diker-Cohen","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.pathol.2018.11.004_bib121","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00125-009-1502-9","article-title":"Efficacy of leptin therapy in the different forms of human lipodystrophy","volume":"53","author":"Chong","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.pathol.2018.11.004_bib122","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/hep.20672","article-title":"Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy","volume":"41","author":"Javor","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.pathol.2018.11.004_bib123","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2337\/diacare.26.1.30","article-title":"Effect of leptin replacement on intrahepatic and intramyocellular lipid content in patients with generalized lipodystrophy","volume":"26","author":"Simha","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pathol.2018.11.004_bib124","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1172\/JCI0215001","article-title":"Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy","volume":"109","author":"Petersen","year":"2002","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.pathol.2018.11.004_bib125","series-title":"Dyslipidemias. Pathophysiology, Evaluation and Management","author":"Garg","year":"2015"},{"key":"10.1016\/j.pathol.2018.11.004_bib126","series-title":"Fitzpatrick's Dermatology in General Medicine","first-page":"755","article-title":"Lipodystrophy","author":"Garg","year":"2012"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302518305270?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302518305270?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T16:25:05Z","timestamp":1758471905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302518305270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":126,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0031302518305270"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2018.11.004","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.736719566.793565868","asserted-by":"object"}]},"ISSN":["0031-3025"],"issn-type":[{"value":"0031-3025","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipodystrophies, dyslipidaemias and atherosclerotic cardiovascular disease","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2018.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V. on behalf of Royal College of Pathologists of Australasia.","name":"copyright","label":"Copyright"}]}}